Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To test the hypothesis that PPAR-gamma agonist, rosiglitazone, induces carotid plaque regression in diabetic ESRD patients on maintenance PD via its anti-inflammatory property.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Diabetic ESRD patients receiving long-term PD treatment, with carotid plaque (defined as focal intima-media thickening >1mm) present on screening ultrasonography

• Patients who provide informed consent for the study

Exclusion Criteria:

• Patients with systemic inflammatory disease such as systemic lupus erythematosus

• Patients with chronic liver disease or cirrhosis

• Patients with current active malignancy

• Patients with chronic rheumatic heart disease or congenital heart disease

• Patients with poor general condition

• Patients with plan for living related kidney transplant within coming 1 year

• Patients with pre-existing class III/IV heart failure,

• Patients with recurrent hypoglycemia

• Patients already on glitazone treatment

• Female patients with pregnancy

• Patients with contraindications for MRI examination including those with pacemaker or metallic implant.